INTERVIEW: The Andrews view: hang on for a big 2003
17 December, 2002 by Pete YoungThe biotech shake-up will intensify in 2003 but the horizon looks inviting on the far side of the wave of mergers expected to roll through the sector over the next 12 to 24 months. That's the view of Prof Peter Andrews, a leading member of the generation which has dramatically reshaped Australian bioscience in the last 15 years and a man who boasts a good track record in sculpting positive environments for young biotechs.
Cochlear scholarship to encourage would-be tertiary students
16 December, 2002 by Melissa TrudingerBionic ear company Cochlear has set up a scholarship to encourage recipients of its cochlear implants to go on to tertiary education.
Xenome in new UK partnership
13 December, 2002 by Pete YoungDrug developer Xenome is adding UK biotech TheraSci to the list of partner firms screening Xenome's venom-based peptide molecules against validated drug targets.
Cytopia close to selecting first drug lead compound
13 December, 2002 by Melissa TrudingerMelbourne drug discovery company Cytopia is close to selecting its first drug lead compound for the treatment of hormone refractory prostate cancer, after getting encouraging results from pre-clinical animal studies.
Virax opens new manufacturing unit
13 December, 2002 by Melissa TrudingerVirax Holdings has opened a new Vector Construction Unit (VCU) located in the School of Biomedical Sciences at Monash University.
Proteome Systems makes a sweet deal with Nestle
12 December, 2002 by Pete YoungSydney-based Proteome Systems has sweetened its chances of cashing in on its expertise in the promising field of sugar-coated proteins by signing a research pact with the world's leading food company, Nestle.
Eiffel cashed-up for 2003
12 December, 2002 by Melissa TrudingerEiffel Technologies has increased its cash reserves to $6.2 million following receipt of partial payment from the sale of their manufacturing operation to Cottee International and a recent share placement.
QrxPharma receives venture funding for pain drugs
11 December, 2002 by Pete YoungA young Australian biotech developing anti-pain and blood-clotting drugs, QRxPharma, has successfully completed a $US5 million financing round conducted by a group of Australian and US venture funds.
Panbio CEO to head Peptech board
11 December, 2002 by Graeme O'NeillSydney biotechnology company Peptech announced today it had appointed Mel Bridges, CEO of Panbio, as chairman of its board.
Biotech projects share the wealth in latest CRC round
11 December, 2002 by Pete YoungA cluster of biotech-intensive entities have been created in the latest round of Cooperative Research Centre (CRC) grants, including a $17.5 million Australian biosecurity centre and a $28 million sugar industry innovation centre.
Patients and patents for Sirtex in Europe
10 December, 2002 by Melissa TrudingerSirtex Medical has treated its first European patient, suffering from advanced secondary liver cancer, with its SIR-Spheres cancer treatment at the Leicester General Hospital, the principal teaching hospital at the University of Leicester in the UK.
Asset sale clears the way for Benitec
10 December, 2002 by Pete YoungGene silencing technology specialist Benitec is tidying up a corporate structure whose complexity led the company to miss an ASX reporting deadline in October.
Chemists told to get proactive about biotech drugs
09 December, 2002 by Melissa TrudingerPharmacists have the opportunity to take on a greater role in patient education and management as the number of biotechnology-derived drugs entering the market increases, but they need to be proactive about it, Dr Ines Krass of the University of Sydney's Faculty of Pharmacy told at the annual meeting of the Australasian Pharmaceutical Science Association today.
New patent approval imminent: Peptech
06 December, 2002 by Graeme O'NeillSydney-based company Peptech has flagged the imminent approval of another of its anti-TNF antibody patents by the US Patent and Trademark Office (USPTO).
Get close to the FDA, Australian companies told
06 December, 2002 by Melissa TrudingerAustralian companies should start talking to the US Food and Drug Administration as early as possible, according to Kendle International's VP of regulatory affairs, Dr Richard Schwen.
